We are live on ! Find out more
VIRX

Viracta Therapeutics, Inc. Common Stock
VIRX

Delisted

VIRX was delisted on the 3rd of February, 2025.

Back to rankings

75 hedge funds and large institutions have $180M invested in Viracta Therapeutics, Inc. Common Stock in 2013 Q2 according to their latest regulatory filings, with 75 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

92% less call options, than puts

Call options by funds: $209K | Put options by funds: $2.58M

Holders
75
Holders Change
+75
Holders Change %
–
% of All Funds
2.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
75
Increased
–
Reduced
–
Closed
–
Calls
$209K
Puts
$2.58M
Net Calls
-$2.37M
Net Calls Change
-$2.37M

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
51
Morgan Stanley
New York
$169K +$173K +155 New
RhumbLine Advisers
52
RhumbLine Advisers
Massachusetts
$154K +$156K +140 New
AllianceBernstein
53
AllianceBernstein
Tennessee
$152K +$155K +139 New
Manulife (Manufacturers Life Insurance)
54
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$149K +$152K +136 New
MLICM
55
Metropolitan Life Insurance Company (MetLife)
New York
$147K +$149K +134 New
NFA
56
Nationwide Fund Advisors
Ohio
$122K +$124K +111 New
PAM
57
Panagora Asset Management
Massachusetts
$116K +$118K +106 New
BA
58
Boston Advisors
Massachusetts
$114K +$117K +105 New
State Board of Administration of Florida Retirement System
59
State Board of Administration of Florida Retirement System
Florida
$108K +$110K +99 New
SO
60
STRS Ohio
Ohio
$105K +$107K +96 New
Invesco
61
Invesco
Georgia
$101K +$104K +93 New
ProShare Advisors
62
ProShare Advisors
Maryland
$100K +$103K +92 New
Group One Trading
63
Group One Trading
Illinois
$95K +$96.9K +87 New
Barclays
64
Barclays
United Kingdom
$84K +$85.8K +77 New
GC
65
Guggenheim Capital
Illinois
$81K +$82.5K +74 New
Goldman Sachs
66
Goldman Sachs
New York
$78K +$80.2K +72 New
BNP Paribas Financial Markets
67
BNP Paribas Financial Markets
France
$63.7K +$64.6K +58 New
Susquehanna International Group
68
Susquehanna International Group
Pennsylvania
$55K +$55.7K +50 New
CCM
69
Chilton Capital Management
Texas
$52K +$53.5K +48 New
NTCOC
70
Northern Trust Company of Connecticut
Connecticut
$39K +$40.1K +36 New
Wells Fargo
71
Wells Fargo
California
$30K +$31.2K +28 New
Bank of America
72
Bank of America
North Carolina
$19K +$18.9K +17 New
ATC
73
Adirondack Trust Company
New York
$5K +$5.57K +5 New
BlackRock
74
BlackRock
New York
$5K +$5.57K +5 New
TRCT
75
Tower Research Capital (TRC)
New York
$5K +$5.57K +5 New
1 2
3

VIRX Hedge Fund Activity: Q2 2013 in Review

75 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q2 2013, worth a combined $180M.

Buyers outnumbered sellers: 75 funds opened new VIRX positions and 0 closed out — a net gain of 75 holders — while 0 added to existing stakes and 0 trimmed.

  • 75 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $180M of Viracta Therapeutics, Inc. Common Stock stock for Q2 2013.
  • 75 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q2 2013 and 0 closed out, a net change of +75 holders.

Based on aggregated 13F filings for Q2 2013.